newsfilter
← Latest News
GlobeNewswire·

Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers

New preclinical data demonstrate that SIL204 treatment produced statistically significant upregulation of FAS (CD95), the immune "death receptor," and statistically significant downregulation of HLA-G, an